[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642057":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":47,"collaborators":19,"id":49,"slug":19,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":78,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GPRC5D PET\u002FCT Imaging With Comparator PET\u002FCT Studies","EXPERIMENTAL","Participants with plasma cell disorders, including multiple myeloma, will undergo GPRC5D-targeted PET\u002FCT imaging following intravenous administration of the investigational GPRC5D-targeted radiotracer. Participants will also undergo 18F-FDG PET\u002FCT and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for intra-individual head-to-head comparison of lesion detection and disease assessment. Safety, biodistribution, tracer uptake characteristics, and imaging performance will be evaluated.",[13],"Diagnostic Test: GPRC5D-Targeted PET\u002FCT Imaging",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","GPRC5D-Targeted PET\u002FCT Imaging",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Lei Kang, M.D, Ph.D","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Tingfei Dr. Gu, M.D","CONTACT","010-83572913","tingfei.gu@stx.ox.ac.uk",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":32},"Zhao Chen, M.D","chenzhao0403@163.com",[34],{"facility":5,"status":19,"city":35,"state":36,"zip":19,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Beijing","Beijing Municipality","China",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100642057",false,"NCT07660939","GPRC5D Targeted PET\u002FCT Imaging in Plasma Cell Disorders","A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET\u002FCT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders","Inclusion Criteria:\n\n* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.\n* Healthy volunteers eligible for PET\u002FCT imaging may also be enrolled.\n* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.\n* Ability to undergo PET\u002FCT imaging procedures.\n* Ability to understand the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* History of other active malignant tumors, unless considered clinically insignificant by the investigator.\n* Pregnant or breastfeeding women.\n* Inability to understand study procedures or comply with imaging examinations.\n* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.",true,"ALL","18 Years","80 Years",{"count":60,"type":61},50,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET\u002FCT imaging in patients with plasma cell disorders, including multiple myeloma.\n\nParticipants will undergo GPRC5D-targeted PET\u002FCT, 18F-FDG PET\u002FCT, and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.\n\nThe study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET\u002FCT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.",[67,68],"Plasma Cell Disorders","Multiple Myeloma (MM)",[70,71,72,73,74,75,76,77],"targeted imaging","molecular imaging","GPRC5D","precise oncology","multiple myeloma","PET\u002FCT","nuclear medicine","precise diagnosis","NOT_YET_RECRUITING","2026-06-16",{"date":81,"type":82},"2026-06-22","ACTUAL",{"date":84,"type":61},"2026-06-25",{"date":86,"type":61},"2027-05-25",{"name":5,"class":6},1]